This trial is evaluating whether Durvalumab will improve 1 primary outcome in patients with Carcinoma. Measurement will happen over the course of From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.
This trial requires 80 total participants across 2 different treatment groups
This trial involves 2 different treatments. Durvalumab is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Stage I endometrial cancer is cured if the patient does not develop recurrent disease after surgery. Stage 2 endometrial cancer can be cured in the long run by surgery. However, endometrial cancer stage 3 or more and stage 4 can not be cured. There is no cure for advanced endometrial cancer." - Anonymous Online Contributor
"Endometrial endometrioid adenocarcinoma shows answer: A combination of a history of endometrial cancer and vaginal bleeding in the later period after menopause, particularly vaginal bleeding per vagin examination or change in menstruation intervals, are good indicators for endometrial endometrioid adenocarcinoma." - Anonymous Online Contributor
"The treatment of endometrial neoplasms depends on the subtype of malignancy (e.g., adenocarcinoma, endocervical intraepithelial neoplasia, or adenocarcinoma with endosseous invasion), the stage of the disease (i.e., stage I endometrial adenocarcinoma requires a lesser amount of therapy than the same disease at a higher stage), and the patients own preferences (e.g., the women can opt for lumpectomy or total hysterectomy instead of chemotherapy treatment)." - Anonymous Online Contributor
"endometrium was more likely in patients with diabetes. Patients with estrogen-producing tumors were more likely to develop a non-mucinous endometrial neoplasm. Estrogen-producing tumors were more likely in nulliparous women with endometrial hyperplasia. The high risk of developing non-mucinous endometrial neoplasms in patients with diabetes may reflect the increased hormonal burden present after pregnancy. These data support the concept that endometrial hormones have a role in endometrial transformation." - Anonymous Online Contributor
"Endometrial neoplasms form when cells of the endometrial lining proliferate at an accelerated rate. Most commonly, it is caused by endometrial hyperplasia and adenocarcinoma. Symptoms include abnormal menorrhagia or menstrual loss." - Anonymous Online Contributor
"The number of patients with EMN seems to be rising in the USA, although the underlying trends are not clear. Because of the significant increase, it seems reasonable to monitor the epidemiology of EMN." - Anonymous Online Contributor
"The authors' current combination therapy has resulted in a durable response in a select group of patients with various ECA and endometrioid ENC. This treatment regimen is a safe combination and adds no inconvenience to the well-tolerated therapy of most patients. Patients have demonstrated the benefit of this therapy as a means of managing patients with ECA and endometrioid endometrial cancer as long as they are able to maintain adherence during the administration. However, in most instances, the maintenance of regular therapy is necessary." - Anonymous Online Contributor
"Results from a recent paper from this initial phase I study support the continuation of a 12-month duration study of durvalumab in metastatic endometrial cancers patients. The safety and tolerability of durvalumab were acceptable." - Anonymous Online Contributor
"Results from a recent clinical trial suggests that durvalumab significantly improves survival time for patients who received a surgical procedure for pelvic adenocarcinoma compared to those who received a placebo while receiving multimodal therapy in addition to surgery. Further studies may be required to determine how to combine chemotherapy and vaccines in a more effective treatment regimen for patients treated surgically." - Anonymous Online Contributor
"The mechanism of action for durvalumab remains unknown, but it appears to function primarily through blocking IFNγ. Whether IFNγ is the primary mediator of the therapeutic effects of durvalumab remains to be seen." - Anonymous Online Contributor
"Results from a recent paper of this study support previous study data suggesting that the sole causative factor in endometrial neoplasms is hyperplasia, followed by dysplasia. The main risk factor for developing endometrial neoplasms is the patient's age at first childbearing." - Anonymous Online Contributor
"Survival in women with endometrioid adenocarcinoma and endometrial carcinosarcoma is significantly better than for patients with other histological types of endometrial carcinoma. Women with endometrioid adenocarcinoma should be evaluated for surgical options with regard to adjuvant treatment and possible resection rather than primary chemotherapy alone." - Anonymous Online Contributor